Pharmaceutical composition for use in the treatment of a neurodegenerative disease

1. A method for treating Parkinson's disease in a patient in need thereof, comprising

administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising desPro 36 Exendin-4(1-39)-Lys 6 -NH 2 (“lixisenatide”) or a pharmaceutically acceptable salt thereof, and

optionally a pharmaceutically acceptable carrier, adjuvant, auxiliary substance or a combination thereof.

2. The method according to claim 1 , wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered parenterally.

3. The method according to claim 1 , wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered in a daily dose of 10 μg to 20 μg.

4. The method according to claim 1 , wherein the Parkinson's disease is associated with neuronal loss.

5. The method of claim 4 , wherein the neuronal loss is a loss of dopaminergic neurons.

6. The method of claim 4 , wherein the neuronal loss is a neuronal loss in the substantia nigra resulting in a lack of dopamine.

7. The method according to claim 1 , wherein the Parkinson's disease is associated with cognitive impairment.

8. The method according to claim 1 , wherein the Parkinson's disease is an early-stage Parkinson's disease.

9. The method according to claim 1 , wherein the progression of the Parkinson's disease is slowed down.

10. The method according to claim 1 , wherein the Parkinson's disease is associated with oxidative stress, inflammatory response, apoptosis, neuronal loss, or a combination thereof.

11. The method according to claim 2 , wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered by subcutaneous injection.

12. The method according to claim 2 , wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered by intramuscular injection.

13. The method according to claim 1 , wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered in a daily dose of 1 μg to 50 μg.

14. The method according to claim 1 , wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered in a daily dose of 5 μg to 40 μg.

15. The method according to claim 1 , wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered in a daily dose of 10 μg to 30 μg.

16. The method according to claim 1 , wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered in a daily dose of 10 μg to 15 μg.

17. The method according to claim 1 , wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered in a daily dose of 15 μg to 20 μg.